Pharmacogenetics of Crohn's disease

Pharmacogenomics

Volumn 9, Issue 7, 2008, Pages 881-893

  Török, Helga Paula ^a   Göke, Burkhard ^a   Konrad, Astrid ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

AZA 6 MP; Crohn's disease; Glucocorticoids; Infliximab; Innovative therapies; Methotrexate; Pharmacogenetics

Indexed keywords

ABT 874; ADALIMUMAB; APILIMOD; AZATHIOPRINE; CALCINEURIN INHIBITOR; CERTOLIZUMAB PEGOL; CNTO 1275; CYTOKINE; DNA; FOLIC ACID; FONTOLIZUMAB; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 6 ANTIBODY; J 695; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 10; RITUXIMAB; STA 5326; STEROID; TACROLIMUS; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; ANTIMETABOLITE; MONOCLONAL ANTIBODY; NUCLEIC ACID SYNTHESIS INHIBITOR;

APOPTOSIS; AUTOPHAGY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLITIS; COLON SURGERY; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; DRUG WITHDRAWAL; ENTERITIS; FLU LIKE SYNDROME; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LIVER HYPERPLASIA; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; NONHUMAN; NONVIRAL GENE THERAPY; PANCREATITIS; PHARMACOGENETICS; POPULATION GENETICS; PREDICTION; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; VEIN OCCLUSION; BIOAVAILABILITY; GENETICS; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES; BIOLOGICAL AVAILABILITY; CROHN DISEASE; GLUCOCORTICOIDS; HUMANS; IMMUNITY, NATURAL; NUCLEIC ACID SYNTHESIS INHIBITORS; PHARMACOGENETICS;

EID: 49949093323     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.7.881     Document Type: Review

References (136)

1. Baumgart DC: What's new in inflammatory bowel disease in 2008? World J. Gastroenterol. 14, 329-330 (2008).
2. Targan SR, Hanauer SB, van Deventer SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis facto α for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337, 1029-1035 (1997).
3. Garrod AE: The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article]. Ya1e J. Biol. Med. 75, 221-231 (2002).
4. Brockmoller J, Tzvetkov MV: Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur. J. Clin. Pharmacol. 64, 133-157 (2008).
5. Kirchheiner J, Seeringer A, Brockmoller J: [State of the art of pharmacogenetic diagnostics in drug therapy]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 49, 995-1003 (2006).
6. Summers RW, Switz DM, Sessions JT et al.: National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77, 847-869 (1979).
7. Katz JA: Treatment of inflammatory bowl disease with corticosteroids. Gastroenterol. Clin. North Am. 33, 171-189, vii (2004).
8. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121, 255-260 (2001).
9. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
10. Farell RJ, Murphy A, Long A et al.: High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fall medical therapy. Gastroenterology 118, 279-288 (2000).
11. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad Sci. USA 97, 3473-3478 (2000).
12. Potocnik U, Ferkolj I, Glavac D, Dean M: Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 5, 530-539 (2004).
13. Urcelay E, Mendoza JL. Martin MC. et al.: MDR1 gene: susceptibility in Spanish Crohn's disease and ulcerative colitis patients. Inflamm. Bowel Dis. 12, 33-37 (2006).
14. Oostenbrug LE, Dijkstra G, Nolte IM et al.: Absence of association between the multidrug resistance (MDR1) gene and inflammatory bowel disease. Scand. J. Gastroenterol. 41, 1174-1182 (2006).
15. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT: Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol. Rev. 206, 260-276 (2005).
16. Onnie CM. Fisher SA, Pattni R et al.: Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behaviour: a case-control and meta-analysis study. Inflamm. Bowel Dis. 12, 263-271 (2006).
17. Cucchiara S, Latiano A, Palmieri O et al.: Polymorphisms of tumor necrosis factor-α but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44, 171-179 (2007).
18. Huizenga NA, Koper JW, de Lange P et al.: A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J. Clin. Endocrinol. Metab. 83, 144-151 (1998).
19. Russcher H, Smit P, van den Akker EL et al.: Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J. Clin. Endocrinol. Metab. 90, 5804-5810 (2005).
20. Patel AS, Karagas MR, Perry AE, Spencer SK, Nelson HH: Gene-drug interaction at the glucocorticoid receptor increases risk of squamous cell skin cancer. J. Invest. Dermatol. 127, 1868-1870 (2007).
21. van Rossum EF. Koper JW, Huizenga NA et al.: A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 51, 3128-3134 (2002).
22. Decorti G, De Iudicibus S, Stocco G et al.: Glucocorticoid receptor polymorphisms in inflammatory bowel disease. Gut 55, 1053-1054 (2006).
23. De Iudicibus S, Stocco G, Martelossi S et al.: Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease. Gut 56, 1319-1320 (2007).
24. Dambacher J, Staudinger T, Seiderer J et al.: Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm. Bowel Dis. 13, 71-82 (2007).
25. Griga T, Wilkens C, Wirkus N, Epplen J, Schmiegel W, Klein W: A polymorphism in the macrophage migration inhibitory factor gene is involved in the genetic predisposition of Crohn's disease and associated with cumulative steroid doses. Hepatogastroenterology 54, 784-786 (2007).
26. Akobeng AK: Review article: the evidence base for interventions used to maintain remission in Crohn's disease. Aliment. Pharmacol. Ther. 27, 11-18 (2008).
27. Schroll S, Sarlette A, Ahrens K, Manns MP, Goke M: Effects of azatthioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro. Regul. Pept. 131, 1-11 (2005).
28. + T lymphocytes. J. Clin. Invest. 111, 1133-1145 (2003).
29. Podolsky DK: Inflammatory bowel disease. N. Engl. J. Med. 347, 417-429 (2002).
30. Mascheretti S, Croucher PJ, Schreiber S: Pharmacogenetics of inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 18, 597-609 (2004).
31. McLeod HL, Siva C: The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 3, 89-98 (2002).
32. Vermeire S: Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment. Pharmacol. Ther. 24(Suppl. 3), 2-10 (2006).
33. Alves S, Ferreira F, Prata MJ, Amorim A: Characterization of three new VNTR alleles in the promoter region of the TPMT gene. Hum. Mutat. 15, 121 (2000).
34. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M: Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of phannacogenetically guided dosing. Clin. Pharmacokinet. 46, 187-208 (2007).
35. Ansari A, Hassan C, Duiey J et al.: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16, 1743-1750 (2002).
36. Colombet JF, Ferrari N, Debuysere H et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118, 1025-1030 (2000).
37. Marinaki AM; Ansari A, Duley JA et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14, 181-187 (2004).
38. Dubinsky MC, Yang H, Hassard PV et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122, 904-915 (2002).
39. Shastri S, Dubinsky MC, Fred Poordad F, Vasiliauskas EA, Geller SA: Early modular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. Arch. Pathol. Lab. Med. 129, 49-53 (2004).
40. Dubinsky MC, Vasiliauskas EA, Singh H et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125, 298-303 (2003).
41. Leonard L: TPMT in the treatment of Crohn's disease with azathioprine. Gut 51, 143-146 (2002).
42. Sayani FA, Prosser C, Bailey RJ, Jacobs P, Fedorak RN: Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can. J Gastroenterol. 19, 147-151 (2005).
43. Winter JW, Gaffney D, Shapiro D et al.: Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 25, 1069-1077 (2007).
44. Fargher EA, Tricker K, Newman W et al.: Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J. Clin, Pharm. Ther. 32, 187-195 (2007).
45. Sumi S, Marinaki AM, Arenas M et al.: Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet. 111, 360-367 (2002).
46. von Ahsen N, Armstrong VW, Behrens C et al.: Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin. Chem. 51, 2282-2288 (2005).
47. Gearry RB, Roberts RL, Barclay ML, Kennedy MA: Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 14, 779-781 (2004).
48. Allorge D, Harridan R, Broly F, Libersa C, Colombel JF: ITPA genotyping test does not Improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 54, 565 (2005).
49. Cotton SC, Sharp L, Little J, Brockton N: Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am. J. Epidermiol. 151, 7-32 (2000).
50. Stocco G, Martelossi S, Barabino A et al.: Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13, 57-64 (2007).
51. Mendoza JL, Urcelay E, Lana R et al.: MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease Inflamm. Bowel Dis. 13, 585-590 (2007).
52. Fedorak RN, Gangl A, Elson CO et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119, 1473-1482 (2000).
53. Alfadhli AA, McDonald JW, Feagan BG: Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. CD003459 (2003).
54. Din S, Dahele A, Fennel J et al.: Use of methotrexate in refractory Crohn's disease: The Edinburgh experience. Inflamm. Bowel Dis. 14(6), 756-762 (2008).
55. Tian H, Cronstein BN: Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull. NYU Hosp. Jt Dis. 65, 168-173 (2007).
56. Chan ES, Cronstein BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 4, 266-273 (2002).
57. Wessels JA Huizinga TW, Guchelaar HJ: Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology 47, 249-255 (2008).
58. Herrlinger KR, Cummings JR, Barnardo MC, Schwab M, Ahmad T, Jewell DP: The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet. Genomics. 15, 705-711 (2005).
59. Mahmud N, Molloy A, McPartlin J et al.: Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut 45, 389-394 (1999).
60. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M: Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100, 3832-3834 (2002).
61. Dervieux T, Kremer J, Lein DO et al.: Contribution of common polymorphisms in reduced folate carrier and γ-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14, 733-739 (2004).
62. Dervieux T, Furst D, Lein DO et al.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50, 2766-2774 (2004).
63. Wessels JA, Kooloos WM, de Jonge R et al.: Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 54, 2830-2839 (2006).
64. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 46, 1520-1524 (2007).
65. Wessels JA, van der Kooij SM, le Cessie S et al.: A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56, 1765-1775 (2007).
66. Ruzicka T, Assmann T, Homey B: Tacrolimus: the drug for the turn of the millennium? Arch. Dermatol. 135, 574-580 (1999).
67. Fellermann K, Ludwig D, Stah M, David-Walek T, Stange EF: Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am. J. Gastroenterol. 93, 1860-1866 (1998).
68. Sandborn WJ, Present DH, Isaacs KL et al.: Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 125, 380-388 (2003).
69. Ng SC, Arebi N, Kamm MA: Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm. Bowel Dis. 13, 129-134 (2007).
70. Hart AL, Plamondon S, Kamm MA: Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm. Bowel Dis. 13, 245-253 (2007).
71. Anglicheau D, Flamant M, Schlageter MH et al.: Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol. Dial. Transplant. 18, 2409-2414 (2003).
72. Anglicheau D, Legendre C, Beaune P, Thervet E: Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 8, 835-849 (2007).
73. Etchelbaum M, Fromm MF, Schwab M: Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26, 180-185 (2004).
74. Hesselink DA, van Schaik RH, van der Heiden IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74, 245-254 (2003).
75. Anglicheau D, Verstuyft C, Laurent-Puig P et al.: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 14, 1889-1896 (2003).
76. Haufroid V, Mourad M, van Kerckhove V et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14, 147-154 (2004).
77. Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ: Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov. Today 12, 125-131 (2007).
78. Arnott ID, Watts D, Satsangi J: Azathioprine and anti-TNFα therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol. Res. 47, 1-10 (2003).
79. Rutgeerts P, D'Haens G, Targan S et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117, 761-769 (2004).
80. Present DH, Rutgeerts P, Targan S et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340, 1398-1405 (1999).
81. Hanauer SB, Feagan BG, Lichtenstein GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002).
82. Sands BE, Anderson FH, Bernstein CN et al.: Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350, 876-885 (2004).
83. Parsi MA, Achkar JP, Richardson S et al.: Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123, 707-713 (2002).
84. Vermeire S, Louis E, Carbonez A et al.: Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's diiease. Am. J. Gastroenterol. 97, 2357-2363 (2002).
85. Taylor KD, Plevy SE, Yang H et al.: ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 120, 1347-1355 (2001).
86. Ogura Y, Bonen DK, Inohara N et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
87. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP: Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am. J. Gastroenterol. 99, 2393-2404 (2004).
88. Inohara N, Ogura Y, Fontalba A et al.: Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278, 5509-5512 (2003).
89. Girardin SE, Boneca IG, Viala J et al.: Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278, 8869-8872 (2003).
90. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50, 206-211 (2002).
91. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121, 1145-1157 (2001).
92. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G: Nod2, a Nod1/ Apaf-1 family member that is restricted to monocytes and activates NF-κB. J. Biol. Chem. 276, 4812-4818 (2001).
93. Beynon VE, Maier K, Faussner A et al.: MDP-induced apoptosis of monocytes is mediated by NOD2/CARD15. Gastroenterology 132 (Suppl. 2), A555 (2007).
94. Vermeire S, Louis E, Rutgeerts P et al.: NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 123, 106-111 (2002).
95. Mascheretti S, Hampe J, Croucher PJ et al.: Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 12, 509-515 (2002).
96. Mascheretti S, Hampe J, Kuhbacher T et al.: Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J. 2, 127-136 (2002).
97. Pierik M, Vermeire S, Steen KV et al.: Tumour necrosis factor-α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment. Pharmacol. Ther. 20, 303-310 (2004).
98. Ozeki T, Furuya Y, Nagano C et al.: Analysis of linkage between lymphotoxin α haplotype and polymorphisms in 5′-flanking region of tumor necrosis factor α gene associated with efficacy of infliximab for Crohn's disease patients. Mutat. Res. 602, 170-174 (2006).
99. Dideberg V, Louis E, Farnir F et al.: Lymphotoxin α gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet. Genomics. 16, 369-373 (2006).
100. Dideberg V, Theatre E, Farnir F et al.: The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet. Genomics. 16, 727-734 (2006).
101. Matsukura H, Ikeda S, Yoshimura N, Takazoe M, Muramatsu M: Genetic polymorphisms of TNF receptor superfamily 1A and 1B (TNFRSF1A and TNFRSF1B) affect responses to infliximab in Crohn's disease patients in Japan. Aliment. Pharmacol. Ther. 27(9), 765-770 (2008).
102. Inoue N, Tamura K, Kinouchi Y et al.: Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 123, 86-91 (2002).
103. Yamazaki K, McGovern D, Ragoussis J et al.: Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum. Mol. Genet. 14, 3499-3506 (2005).
104. Hlavaty T, Pierik M, Henckaerts L et al.: Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 22, 613-626 (2005).
105. Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S: Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm. Bowel Dis. 13, 372-379 (2007).
106. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003).
107. Louis E, El Ghoul Z, Vermeire S et al.: Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 19, 511-519 (2004).
108. Willot S, Vermeire S, Ohresser M et al.: No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet. Genomics 16, 37-42 (2006).
109. Hanauer SB, Sandborn WJ, Rutgeerts P et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130, 323-333 (2006).
110. Sandborn WJ, Hanauer SB, Rutgeerts P et al.: Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56, 1232-1239 (2007).
111. Colombel JF, Sandborn WJ, Rutgeerts P et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52-65 (2007).
112. Sandborn WJ, Feagan BG, Stoinov, S et al.: Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 228-238 (2007).
113. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al.: Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357, 239-250 (2007).
114. Hommes DW, Mikhajlova TL, Stoinov S et al.: Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55, 1131-1137 (2006).
115. Reinisch W, Hommes DW, van Assche G et al.: A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn's disease. Gut 55, 1138-1144 (2006).
116. Ito H, Takazoe M, Fukuda Y et al.: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989-996 (2004).
117. Schreiber S, Fedorak RN, Nielsen OH et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119, 1461-1472 (2000).
118. Braat H, Rottiers P, Hommes DW et al.: A Phase I trial with transgenic bacteria expressing Interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 754-759 (2006).
119. Mannon PJ, Fuss IJ, Mayer L et al.: Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069-2079 (2004).
120. Yen D, Cheung J, Scheerens H et al.: IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116, 1310-1316 (2006).
121. Hue S, Ahern P, Buonocore S et al.: Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203, 2473-2483 (2006).
122. Duerr RH, Taylor KD, Brant SR et al.: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006).
123. Burakoff R, Barish CF, Riff D et al.: A Phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm. Bowel Dis. 12, 558-565 (2006).
124. Bowman EP, Chackerian AA, Cua, DJ Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr. Opin. Infect. Dis. 19, 245-252 (2006).
125. Shih DQ, Targan SR: Immunopathogenesis of inflammatory bowel disease. World J. Gastroenterol. 14, 390-400 (2008).
126. Sandborn WJ, Colombel JF, Enns R et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353, 1912-1925 (2005).
127. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ: Sargramostim for active Crohn's disease. N. Engl. J. Med. 352, 2193-2201 (2005).
128. Rachmilewitz D, Karmeli F, Takabayashi K et al.: Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 122, 1428-1441 (2002).
129. Rachmilewitz D, Katakura K, Karmeli F et al.: Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126, 520-528 (2004).
130. Marks DJ, Harbord MW, MacAllister R et al.: Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367, 668-678 (2006).
131. Hugot JP, Chamaillard M, Zouali H et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
132. Browning BL, Huebner C, Petermann I et al.: Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am. J. Gastroenterol. 102, 2504-2512 (2007).
133. Torok HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C: Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 127, 365-366 (2004).
134. Hampe J, Franke A, Rosenstiel P et al.: A genome-wide association scan of nonsynonymous SNPs Identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39, 207-211 (2007).
135. Welcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
136. Nikolaus S, Schreiber S: Diagnostics of Inflammatory bowel disease. Gastroenterology 133, 1670-1689 (2007).